Ipilumumab Plus Pembrolizumab Vs Pembrolizumab Alone In PdL1 More Than 50 Percentage Which Is Better

12 Mar, 2021

Dr. Rajesh Bollam

Image

#Lungcancer

#Immunotherapy

#is more always better ?

Ipilumumab plus pembrolizumab vs pembrolizumab alone in pdL1 more than 50 percentage

Which is better

Single agent pembrolizumab is better

🛎#WCLC20 #LCSM KN589

The addition of IPI in #lungCancer failed AGAIN to improve survival combined w/ another ICI (here Pembro)

🔻NO OS & PFS benefit (HR>1)

🔻High % of irAEs (20.2 vs 7.8%)

Mono ICI remains t standard in PDL1≥50%

📑full JCO just out👇🏻

Add a comment